RY 161.2 -1.8509% SHOP 138.97 -5.2176% TD 86.42 -0.9967% ENB 63.565 0.1024% BN 74.36 -4.0145% TRI 244.82 -0.9027% CNQ 43.695 -1.3211% CP 100.11 -2.4269% CNR 140.04 -1.8641% BMO 137.15 -1.267% BNS 68.325 -1.2645% CSU 4591.96 -1.5043% CM 80.13 -2.3043% MFC 44.03 -1.1672% ATD 69.99 -0.5683% NGT 68.92 -0.4478% TRP 68.76 -0.5064% SU 54.77 -0.9405% WCN 276.03 -0.4867% L 197.94 0.7226%
Last update at 2025-03-28T18:53:00Z
Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD
Thu 27 Mar 25, 01:25 PMMerit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
Wed 26 Mar 25, 02:36 PMMerit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
Tue 18 Mar 25, 01:25 PMMMSI Announces Commencement of Patient Enrollment in PREEMIE Study
Fri 14 Mar 25, 01:15 PMFirst Patient Enrolled in Merit Medical’s PREEMIE Study
Mon 10 Mar 25, 01:25 PMMerit Medical Systems Full Year 2024 Earnings: EPS Misses Expectations
Thu 27 Feb 25, 11:50 AMQ4 2024 Merit Medical Systems Inc Earnings Call
Wed 26 Feb 25, 05:13 PMMMSI Stock Gains in Pre-Market Post Q4 Earnings Beat, Margins Up
Wed 26 Feb 25, 04:06 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 82.63M | 53.92M | -13.23100M | 2.19M | 49.52M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | 74.52M | 48.45M | -9.84300M | 5.45M | 42.02M |
| Selling general administrative | 342.52M | 335.69M | 297.72M | 327.27M | 276.02M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 519.10M | 485.33M | 401.18M | 432.37M | 394.77M |
| Reconciled depreciation | 92.20M | 95.78M | 106.82M | 104.36M | 69.55M |
| Ebit | 87.56M | 60.92M | -62.57500M | -65.70700M | -9.06400M |
| Ebitda | 194.67M | 172.44M | 44.24M | 38.65M | 60.48M |
| Depreciation and amortization | 107.10M | 111.53M | 106.82M | 104.36M | 69.55M |
| Non operating income net other | 1.41M | -1.73800M | -1.67500M | - | 1.26M |
| Operating income | 87.56M | 60.92M | -62.57500M | -65.70700M | 58.62M |
| Other operating expenses | 1049.92M | 996.36M | 917.96M | 955.38M | 823.53M |
| Interest expense | 6.34M | 5.26M | 9.99M | 12.41M | 10.36M |
| Tax provision | 8.11M | 5.46M | -3.38800M | -3.25800M | 7.50M |
| Interest income | 0.44M | 0.77M | 0.60M | 0.29M | 1.20M |
| Net interest income | -5.90000M | -4.49200M | -9.39000M | -12.70400M | -9.16100M |
| Extraordinary items | - | - | - | - | -3.20000M |
| Non recurring | 8.89M | 14.32M | 55.44M | - | 1.30M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 8.11M | 5.46M | -3.38800M | -3.25800M | 7.50M |
| Total revenue | 1150.98M | 1074.75M | 963.88M | 994.85M | 882.75M |
| Total operating expenses | 418.04M | 406.94M | 355.26M | 392.89M | 335.55M |
| Cost of revenue | 631.88M | 589.42M | 562.70M | 562.49M | 487.98M |
| Total other income expense net | -4.93400M | -6.99900M | 49.34M | 67.90M | -0.54000M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 74.52M | 48.45M | -9.84300M | 5.45M | 42.02M |
| Net income applicable to common shares | 74.52M | 48.45M | -9.84300M | 5.45M | 42.02M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2325.24M | 1663.97M | 1648.29M | 1664.40M | 1757.32M |
| Intangible assets | 325.88M | 275.87M | 319.27M | 367.92M | 445.31M |
| Earning assets | - | - | - | - | - |
| Other current assets | 26.20M | 22.32M | 16.15M | 13.12M | 12.50M |
| Total liab | 1123.24M | 519.57M | 608.50M | 705.82M | 807.38M |
| Total stockholder equity | 1202.00M | 1144.40M | 1039.80M | 958.58M | 949.94M |
| Deferred long term liab | - | 33.73M | 49.61M | 50.12M | - |
| Other current liab | 120.45M | 129.89M | 161.55M | 114.76M | 107.98M |
| Common stock | 638.15M | 675.17M | 641.53M | 606.22M | 587.02M |
| Capital stock | 638.15M | 675.17M | 641.53M | 606.22M | 587.02M |
| Retained earnings | 575.18M | 480.77M | 406.26M | 357.80M | 368.22M |
| Other liab | - | 52.43M | 76.29M | 102.69M | 120.73M |
| Good will | 382.24M | 359.82M | 361.74M | 363.53M | 353.19M |
| Other assets | - | 31.93M | 47.50M | 227.71M | 28.12M |
| Cash | 589.14M | 58.41M | 67.75M | 56.92M | 44.32M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 203.56M | 220.65M | 236.28M | 185.00M | 181.66M |
| Current deferred revenue | 5.09M | - | - | 4.60M | - |
| Net debt | 302.22M | 210.34M | 247.28M | 378.15M | 479.43M |
| Short term debt | 12.09M | 22.25M | 19.11M | 20.40M | 19.05M |
| Short long term debt | - | 11.25M | 8.44M | 7.50M | 7.50M |
| Short long term debt total | 891.36M | 268.75M | 315.03M | 435.07M | 523.75M |
| Other stockholder equity | - | -11.55000M | -7.99100M | -5.45200M | -0.29400M |
| Property plant equipment | - | 382.98M | 437.57M | 382.73M | 459.03M |
| Total current assets | 1108.47M | 529.08M | 482.21M | 429.71M | 454.54M |
| Long term investments | 19.06M | 15.58M | 14.71M | 12.04M | 17.13M |
| Net tangible assets | - | 508.70M | 358.79M | 227.13M | 151.44M |
| Short term investments | 1.50M | - | - | - | - |
| Net receivables | 189.26M | 178.45M | 172.84M | 157.96M | 168.53M |
| Long term debt | 823.01M | 186.76M | 234.40M | 343.72M | 431.98M |
| Inventory | 303.87M | 265.99M | 221.92M | 198.02M | 225.70M |
| Accounts payable | 65.94M | 68.50M | 55.62M | 49.84M | 54.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -11.33400M | -11.55000M | -7.99100M | -5.45200M | -5.29400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 675.17M | 641.53M | 606.22M | 587.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 480.77M | 406.26M | 357.80M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 32.27M | 28.78M | 26.71M | 25.63M | 24.33M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1216.77M | 1134.88M | 1166.08M | 1234.69M | 1302.78M |
| Capital lease obligations | 68.35M | 70.74M | 72.19M | 83.84M | 84.26M |
| Long term debt total | - | 186.76M | 234.40M | 343.72M | 431.98M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -184.33300M | -57.39700M | -37.16100M | 0.25M | -134.48100M |
| Change to liabilities | - | 12.66M | 6.05M | 0.33M | -2.29500M |
| Total cashflows from investing activities | - | -57.39700M | -37.16100M | -58.65200M | -134.48100M |
| Net borrowings | - | -44.93800M | -108.50000M | -88.37500M | 44.50M |
| Total cash from financing activities | 559.27M | -60.26000M | -98.43500M | -95.70600M | 33.53M |
| Change to operating activities | - | -27.06300M | -17.83800M | -4.78600M | -4.94500M |
| Net income | 94.41M | 74.52M | 48.45M | -9.84300M | 5.45M |
| Change in cash | 528.58M | -7.19200M | 10.83M | 12.60M | -23.03900M |
| Begin period cash flow | 60.56M | 67.75M | 56.92M | 44.32M | 67.36M |
| End period cash flow | 589.14M | 60.56M | 67.75M | 56.92M | 44.32M |
| Total cash from operating activities | 145.15M | 114.29M | 147.23M | 165.27M | 77.81M |
| Issuance of capital stock | 24.78M | 20.07M | 21.31M | 6.63M | 6.25M |
| Depreciation | 101.29M | 92.20M | 95.78M | 106.82M | 104.36M |
| Other cashflows from investing activities | - | -12.36800M | -2.05100M | -12.91400M | 0.25M |
| Dividends paid | - | 2.47M | 0.58M | 0.87M | - |
| Change to inventory | -32.10500M | -47.92900M | -25.18300M | 29.43M | -27.04400M |
| Change to account receivables | -9.54500M | -15.11600M | -8.61800M | 10.43M | -17.90000M |
| Sale purchase of stock | -5.12300M | -2.47400M | -0.57600M | -0.86600M | 6.25M |
| Other cashflows from financing activities | 1162.58M | -30.44400M | -10.08900M | 56.39M | 229.44M |
| Change to netincome | - | 39.77M | 20.83M | 175.11M | 22.78M |
| Capital expenditures | 36.70M | 45.03M | 27.94M | 49.28M | 81.50M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -3.36600M | 11.63M | 10.91M | - |
| Change in working capital | -70.02200M | -71.39800M | -17.83800M | 34.24M | -55.72500M |
| Stock based compensation | 21.33M | 18.04M | 16.09M | 14.34M | 9.38M |
| Other non cash items | 10.78M | 15.86M | 9.37M | 31.02M | 26.79M |
| Free cash flow | 108.45M | 69.26M | 119.29M | 115.99M | -3.68400M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MMSI Merit Medical Systems Inc |
-0.36 0.35% | 102.91 | 47.11 | 21.93 | 3.35 | 3.51 | 3.60 | 19.76 |
| ISRG Intuitive Surgical Inc |
-18.65 3.67% | 489.25 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-1.52 1.04% | 144.05 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
-0.59 0.20% | 287.87 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.56 0.68% | 227.15 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
1600 West Merit Parkway, South Jordan, UT, United States, 84095
| Name | Title | Year Born |
|---|---|---|
| Mr. Fred P. Lampropoulos | Founder, Chairman, CEO & Pres | 1950 |
| Mr. Raul Parra Jr., CPA | CFO & Treasurer | 1979 |
| Mr. Brian G. Lloyd | Chief Legal Officer & Corp. Sec. | 1961 |
| Mr. Joseph C. Wright | Chief Commercial Officer | 1970 |
| Mr. Neil Peterson | Chief Operating Officer | NA |
| Mr. Jason Treft | Chief Technology Officer | NA |
| Mr. Joseph Pierce | Chief Information Officer | NA |
| Mr. Michel J. Voigt | Chief HR Officer | 1973 |
| Mr. John Knorpp | Chief Regulatory Affairs Officer | NA |
| Dr. Nicole Priest | Chief Wellness Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA
AU
UK
US
NZ
IND
Please wait processing your request...